# Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants

> **NCT04381689** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Il-Yang Pharm. Co., Ltd.** · enrollment: 245 (estimated)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** IL-YANG FLU Vaccine Prefilled Syringe INJ.
- **BIOLOGICAL:** Fluarix Tetra Pre-filled Syringe

## Key facts

- **NCT ID:** NCT04381689
- **Lead sponsor:** Il-Yang Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-23
- **Primary completion:** 2025-05-20
- **Final completion:** 2026-05-31
- **Target enrollment:** 245 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04381689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04381689, "Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04381689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*